Assays for predicting and monitoring responses to lung cancer immunotherapy

摘要: Immunotherapy has become a key strategy for cancer treatment, and two immune checkpoints, namely, programmed cell death 1 (PD-1) its ligand (PD-L1), have recently emerged as important targets. The interaction blockade of PD-1 PD-L1 demonstrated promising activity antitumor efficacy in early phase clinical trials advanced solid tumors such non-small lung (NSCLC). Many types multiple tissues express well several tumor types, thereby suggesting that the may play roles inhibiting responses throughout body. Therefore, is critical immunomodulating component within microenvironment, but correlation between expression prognosis controversial. More evidence required to support use potential predictive biomarker. Clinical measured by immunohistochemistry (IHC) with different antibodies, assessment not yet standardized. Some commercial antibodies lack specificity their reproducibility been fully evaluated. Further studies are clarify optimal IHC assay predict monitor PD-1/PD-L1 pathway.